% alzhub.org library filter
% Source: https://alzhub.org/research?author=Sperling+R&design=trial
% 7 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{salloway2014-24450891,
  author  = {Salloway, S. and Sperling, R. and Fox, N. C. and Blennow, K. and Klunk, W. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease}},
  journal = {The New England journal of medicine},
  year    = {2014},
  doi     = {10.1056/nejmoa1304839},
  pmid    = {24450891},
  url     = {https://doi.org/10.1056/nejmoa1304839}
}

@article{salloway2009-19923550,
  author  = {Salloway, S. and Sperling, R. and Gilman, S. and Fox, N. C. and Blennow, K. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2009},
  doi     = {10.1212/wnl.0b013e3181c67808},
  pmid    = {19923550},
  url     = {https://doi.org/10.1212/wnl.0b013e3181c67808}
}

@article{salloway2011-21917766,
  author  = {Salloway, S. and Sperling, R. and Keren, R. and Porsteinsson, A. P. and van Dyck, C. H. and Tariot, P. N. and Gilman, S. and Arnold, D. and others},
  title   = {{A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2011},
  doi     = {10.1212/wnl.0b013e3182309fa5},
  pmid    = {21917766},
  url     = {https://doi.org/10.1212/wnl.0b013e3182309fa5}
}

@article{liu2015-26208959,
  author  = {Liu, E. and Schmidt, M. E. and Margolin, R. and Sperling, R. and Koeppe, R. and Mason, N. S. and Klunk, W. E. and Mathis, C. A. and others},
  title   = {{Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials}},
  journal = {Neurology},
  year    = {2015},
  doi     = {10.1212/wnl.0000000000001877},
  pmid    = {26208959},
  url     = {https://doi.org/10.1212/wnl.0000000000001877}
}

@article{vandyck2025-41355080,
  author  = {van Dyck, C. H. and Sperling, R. and Johnson, K. and Dhadda, S. and Kanekiyo, M. and Li, D. and Gee, M. and Hersch, S. and Irizarry, M. and Kramer, L.},
  title   = {{Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension study}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70905},
  pmid    = {41355080},
  url     = {https://doi.org/10.1002/alz.70905}
}

@article{sperling2012-22305802,
  author  = {Sperling, R. and Salloway, S. and Brooks, D. J. and Tampieri, D. and Barakos, J. and Fox, N. C. and Raskind, M. and Sabbagh, M. and others},
  title   = {{Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis}},
  journal = {The Lancet. Neurology},
  year    = {2012},
  doi     = {10.1016/s1474-4422(12)70015-7},
  pmid    = {22305802},
  url     = {https://doi.org/10.1016/s1474-4422(12)70015-7}
}

@article{boxer2023-37848035,
  author  = {Boxer, A. L. and Sperling, R.},
  title   = {{Accelerating Alzheimer's therapeutic development: The past and future of clinical trials}},
  journal = {Cell},
  year    = {2023},
  doi     = {10.1016/j.cell.2023.09.023},
  pmid    = {37848035},
  url     = {https://doi.org/10.1016/j.cell.2023.09.023}
}